Roivant builds and spins off biotech companies ('Vants').
Roivant Sciences Ltd. (ROIV) is expected to report earnings on Monday, November 9, 2026, before the open. Estimated release time 07:14 ET. Consensus EPS estimate is $-0.41.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-06 | Jun 2026 qtr | $-0.30 | $-0.33 | — | $1.44M |
| 2026-05-20 | Mar 2026 qtr | $-0.29 | $-0.28 | +3.5% | $2.52M |
| 2026-02-06 | Dec 2025 qtr | $-0.30 | $-0.24 | — | $2.00M |
| 2025-11-10 | Sep 2025 qtr | $-0.32 | $-0.20 | — | $1.57M |
| 2025-02-10 | Dec 2024 qtr | $-0.25 | $-0.13 | — | $9.02M |
| 2024-08-08 | Jun 2024 qtr | $-0.24 | $0.12 | — | $55.13M |
| 2024-05-30 | Mar 2024 qtr | $-0.26 | $-0.23 | +13.0% | $28.93M |
| 2024-02-13 | Dec 2023 qtr | $-0.31 | $-0.21 | — | $37.14M |
ROIV has beaten consensus EPS in 2 of its last 2 scored quarters.
See ROIV on the live calendar →